Daniela Oniciu

Biography

 Dr. Oniciu serves as VP of Preclinical R&D and Manufacturing. Dr. Oniciu has more than 30 years of experience in chemical research, with her last sixteen years dedicated to pharmaceutical research and development in various therapeutic areas including: cardiovascular disease, metabolic disorders and cholesterol management, neuroprotective drug analogs, prodrugs and chemical delivery systems. Most recently she has focused on preclinical R&D and CMC related regulatory affairs for pharmaceuticals and fine chemicals that span small molecules. Prior to that, Dr. Oniciu was appointed as Senior Director of Chemistry at Cerenis Therapeutics Holding SA, a French biotech dedicated to the development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. At Cerenis, Dr. Oniciu participated in the financing of the company with top tier investors, leading to €92M out of the total of €117M in equity raised by Cerenis. Prior to joining Cerenis, Dr. Oniciu was Senior Director of Chemical R&D at Esperion Therapeutics Inc., where she was a co-inventor of small molecule drug candidates including ETC-1002, and served as co-chair of the preclinical research team. Following the acquisition of Esperion by Pfizer Inc., Dr. Oniciu served as Associate Director of Chemistry at Pfizer. Prior to joining Esperion in 2001, Dr. Oniciu was co-founder of a custom research organization, Alchem Laboratories Corporation, one of the first CROs in the United States, specialized in drug design and process development support for the pharmaceutical industry. In addition, Dr. Oniciu is Courtesy Professor of Chemistry at the University of Florida at Gainesville since 2004. Dr. Oniciu holds a Ph.D. in organic chemistry from the Polytechnic University of Bucharest (Romania), and a M.S. in Organic Chemistry and Chemical Engineering from the same University.

Research Interest

 Chemical research,Pharmaceutical research and development